Related Experiment Video
Updated: May 29, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer
D De Ruysscher1, B Reymen, A Van Baardwijk
1Department of Radiation Oncology, (MAASTRO clinic), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands. dirk.deruysscher@maastro.nl
Improved radiotherapy techniques, including stereotactic body radiotherapy (SBRT) and hyperfractionated accelerated radiotherapy (INDAR), enhance local tumor control and survival rates for non-small cell lung cancer (NSCLC). These methods deliver higher radiation doses in shorter overall treatment times, improving efficacy without increasing side effects.
Area of Science:
- Radiation Oncology
- Medical Physics
- Oncology
Background:
- Improved local tumor control correlates with increased survival rates in non-small cell lung cancer (NSCLC).
- Radiotherapy exhibits a dose-response relationship, where higher doses improve local tumor control.
- Prolonging treatment time beyond 4-5 weeks reduces radiotherapy effectiveness due to tumor cell proliferation.
Purpose of the Study:
- To explore strategies for local tumor eradication in NSCLC.
- To investigate the efficacy of delivering high-dose radiation within short overall treatment times.
- To evaluate advanced radiotherapy schedules like SBRT and hyperfractionated regimens.
Main Methods:
- Stereotactic body radiotherapy (SBRT) utilizes few large radiation doses for high biological doses in short treatment times.
- Hyperfractionated radiotherapy schedules deliver 2-3 smaller fractions daily.
- Individualized hyperfractionated accelerated radiotherapy (INDAR) has been developed for curative intent.
Main Results:
- SBRT achieves over 90% tumor control in stage I NSCLC.
- Hyperfractionated schedules demonstrated superior 5-year survival compared to standard regimens without increased side effects.
- INDAR enables curative treatment for large tumors with minimal side effects.
Conclusions:
- Optimizing radiation dose and overall treatment time is crucial for NSCLC management.
- SBRT and hyperfractionated radiotherapy, including INDAR, represent effective strategies for improving outcomes in NSCLC.
- INDAR shows promise when combined with chemotherapy or cetuximab for advanced NSCLC.
